A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I [0.03%]
Palonosetron、阿瑞匹坦和奥氮平联合用药防治铂类方案引起的恶心呕吐的多中心Ⅱ期临床研究：PATROL-I研究
Daiki Tsuji,Shigeru Nakagaki,Itsuki Yonezawa et al.
Daiki Tsuji et al.
Dexamethasone is one of the key antiemetic agents and is widely used even now. However, dexamethasone has been associated with several adverse reactions even after short-term administration. Therefore, developing a steroid-free antiemetic r...
Clinical Trial
Investigational new drugs. 2024 Feb;42(1):44-52. DOI:10.1007/s10637-023-01414-y 2024
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma [0.03%]
BMS-986，205和尼伏木单抗一线治疗肝细胞癌I/II期临床试验
Jasmine C Huynh,May Cho,Arta Monjazeb et al.
Jasmine C Huynh et al.
Background: Indoleamine-2,3-dioxygenase (IDO) helps orchestrate immune suppression and checkpoint inhibitor resistance in hepatocellular carcinoma (HCC). BMS-986,205 is a novel oral drug that potently and selectively inhi...
Clinical Trial
Investigational new drugs. 2024 Feb;42(1):35-43. DOI:10.1007/s10637-023-01416-w 2024
Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study [0.03%]
中国胆管癌分子分型及预后分析：一项回顾性单中心研究
Changkun Zhang,Xia You,Qin Zhang et al.
Changkun Zhang et al.
Cholangiocarcinoma (CCA) is a primary malignancy which is often diagnosed when it is advanced and inoperable due to the lack of effective biomarkers and poor sensitivity of clinical diagnosis. Molecular profiling may provide information for...
Observational Study
Investigational new drugs. 2024 Feb;42(1):24-34. DOI:10.1007/s10637-023-01394-z 2024
Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancer [0.03%]
胃癌免疫新辅助治疗：免疫检查点抑制剂的新兴范例——胃癌免疫新辅助治疗
Guoliang Yao,Jianyong Yuan,Qianqian Duan et al.
Guoliang Yao et al.
Advances in immune checkpoint inhibitors (ICIs) have enabled more effective treatment for individuals with various types of solid tumors. Given the improved survival benefit and acceptable safety profile of ICIs in advanced gastric cancer, ...
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide [0.03%]
内吞体循环抑制剂下调雄激素受体并可与恩杂鲁胺协同发挥作用
Kelsey A Fletcher,Mai H Alkurashi,Andrew J Lindsay
Kelsey A Fletcher
Prostate cancer is the second most frequent cancer diagnosed in men, and accounts for one-fifth of cancer associated deaths worldwide. Despite the availability of effective prostate cancer therapies, if it is not cured by radical local trea...
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines [0.03%]
ATR抑制剂berzosertib能够增强射线和药物对口腔鳞状细胞癌细胞系的杀伤作用
Julia Schnoell,Carmen Sparr,Sega Al-Gboore et al.
Julia Schnoell et al.
Alterations in the DNA damage response play a crucial role in radio- and chemoresistance of neoplastic cells. Activation of the Ataxia telangiectasia and Rad3-related (ATR) pathway is an important DNA damage response mechanism in head and n...
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer [0.03%]
免疫检查点抑制剂相关心肌炎的临床特征及其对晚期非小细胞肺癌预后的影响
Lan Xu,Manyi Xu,Wei Sun et al.
Lan Xu et al.
Myocarditis is a rare immune-related adverse events (irAEs) with high mortality rates, with few reports on its clinical characteristics and prognostic impact. This study designed to explore the associations between cardiac parameters and ou...
Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis [0.03%]
派姆单抗致噬血细胞性淋巴组织细胞增生症的临床特点、治疗及管理
Chunjiang Wang,Wei Sun,Zuojun Li et al.
Chunjiang Wang et al.
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare and fatal adverse reaction to pembrolizumab. The clinical characteristics of pembrolizumab induced HLH are unknown. Exploring the clinical features of pembrol...
Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial [0.03%]
皮米哲利布（成纤维细胞生长因子受体1-3的选择性抑制剂）单药治疗在中国晚期实体瘤患者中的药代动力学、药效学和疗效：一项一期临床试验
Ting Deng,Le Zhang,Yehui Shi et al.
Ting Deng et al.
Pemigatinib is a selective fibroblast growth factor receptor (FGFR)1-3 inhibitor and has demonstrated acceptable tolerability and clinical activity in advanced solid tumors in Western population. This phase I trial evaluated pharmacokinetic...
Antitumor activity of the new tyrphostin briva against BRAFV600E-mutant colorectal carcinoma cells [0.03%]
新型 tyrphostin 类衍生物 briva 对 BRAFV600E 突变结直肠癌细胞的抗肿瘤作用
Khaled Saleh,Mai Al Sakhen,Sana Kanaan et al.
Khaled Saleh et al.
Because of a reduced sensitivity of BRAF-mutant colorectal cancers to BRAF inhibitor treatment when compared with BRAF-mutant melanoma, it is essential to develop efficient drugs to cope with this disease. The new 2-(4-bromophenyl)-3-arylac...